| Literature DB >> 35637519 |
Ye-Seul Lee1, Song-Yi Kim2, Mariah Kim3, Minseo Kim2, Jiyoon Won4, Hyangsook Lee5, Myeong Soo Lee4, Younbyoung Chae6.
Abstract
OBJECTIVE: The description of controls is important in acupuncture clinical trials to interpret its effectiveness without fallacy. This paper aims to evaluate the reporting quality of acupuncture studies on the characteristics of sham needles. STUDY DESIGN ANDEntities:
Keywords: Acupuncture; CONSORT; Control; Placebos; STRICTA; TIDieR
Year: 2022 PMID: 35637519 PMCID: PMC9153153 DOI: 10.1186/s13020-022-00608-5
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 4.546
Items used in this study for systematic evaluation
| Items | Corresponding items in guidelines | |||
|---|---|---|---|---|
| Categories | Descriptions | STRICTA | TIDieR | |
| I. Type of sham needle | 1a | Type of sham needle. (e.g., Streitberger needle, Park needle, Takakura needle, cocktail picks) | 1a | 1 |
| 1b | Rationale for using the chosen sham needle | 1b, 6a | 2 | |
| II. Details of sham needle | 2a | Number of sham needling per subject per session | 2a | 8 |
| 2b | Are the depths of insertion reported? | 6 g | ||
| 2c | Response sought (e.g., de qi or muscle twitch response) | 2d | 6 | |
| 2d | Sham needle stimulation | 2e | 6 | |
| 2e | Sham needle retention | 2f | 6 | |
| 2f | Details of other interventions administered in addition to sham needles | 4a | 6 | |
| III. Location of sham needle | 3a | Location of sham needling (e.g., acupoints/non-acupoints, exact location of the sites) | 2b | 6 |
| 3b | Is it explicit that the points are unilateral or bilateral? | 6e | 6 | |
| 3c | Rationale for the location chosen for sham needling | 1b, 6a | 2 | |
| IV. Treatment regimen | 4a | Number of placebo sessions | 3a | 8 |
| 4b | Frequency and duration of placebo sessions | 3b | 8 | |
| 4c | Total trial period for placebo group/sessions | 3a, 3b | ||
| V. Practitioner | 5a | Is the same practitioner administering both treatment and control groups? | 5 | |
| 5b | Did practitioner and the patient have discussions prior to the treatment? (Doctor-patient relationship) | |||
| 5c | Was there any discussion regarding the symptoms during the treatment? | |||
| VI. Protocol and settings | 6a | Instruction and information given by the practitioner to the patients (are the explanations that were given to participants of treatment and control interventions provided?) | 6b | 3 |
| 6b | Was the introduction to participants explained in the paper? | |||
| 6c | Did the instruction and information include the term “placebo” or “sham"? | |||
| 6d | Type of blinding (e.g., only the patients, double-blinding) | |||
| 6e | Was the method of blinding sham needle to patients elaborated? | |||
| 6f | Modification of the needling procedure if there was any, and reason for the modification | 10 | ||
| 6 g | Assessment of the intervention adherence or fidelity, and blinding | 12 | ||
| 6 h | Any differences in the settings between treatment and control groups | |||
Fig. 1PRISMA (preferred reporting items for systematic reviews and meta-analyses) flowchart showing the flow of articles through the study
Fig. 2A Heatmap showing the distribution of reporting rates in each time period by each item. Items in “treatment regimen” category were reported in more than 50% of the studies throughout all time periods, and items in “practitioner” category and “protocol and settings” category were reported in less than 50% of the studies. B Bar graph showing the overall reporting scores by categories. The most reported category was “treatment regimen”, and the least reported category was “practitioner.” *p-value < 0.05. **p-value < 0.01
Fig. 3Distribution of the overall reporting scores over time. The red line shows the linear regression value between published date and reporting scores (β = 0.008, p-value = 0.358). The reporting qualities on sham needles did not improve over time